Boston Trust Walden Corp Sells 9,056 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Boston Trust Walden Corp lowered its position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 2.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 317,246 shares of the medical instruments supplier's stock after selling 9,056 shares during the period. Boston Trust Walden Corp owned 1.30% of ICU Medical worth $49,227,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Allworth Financial LP boosted its stake in ICU Medical by 100.0% in the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier's stock worth $36,000 after purchasing an additional 100 shares in the last quarter. Hexagon Capital Partners LLC raised its holdings in ICU Medical by 162.7% in the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier's stock worth $36,000 after buying an additional 122 shares during the last quarter. Venturi Wealth Management LLC lifted its stake in shares of ICU Medical by 1,510.0% in the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier's stock worth $59,000 after buying an additional 302 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of ICU Medical during the third quarter valued at approximately $72,000. Finally, GAMMA Investing LLC increased its position in shares of ICU Medical by 83.6% during the third quarter. GAMMA Investing LLC now owns 571 shares of the medical instruments supplier's stock valued at $104,000 after acquiring an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company's stock.

ICU Medical Stock Performance

ICUI stock traded down $1.74 during trading on Friday, reaching $156.65. The stock had a trading volume of 134,878 shares, compared to its average volume of 203,083. The firm has a market cap of $3.83 billion, a PE ratio of -34.28 and a beta of 0.63. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The stock's 50 day moving average is $160.72 and its two-hundred day moving average is $163.23. ICU Medical, Inc. has a 52 week low of $93.36 and a 52 week high of $196.26.

Insider Activity at ICU Medical

In other ICU Medical news, COO Christian B. Voigtlander sold 1,962 shares of the business's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $169.08, for a total transaction of $331,734.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David C. Greenberg sold 972 shares of the company's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total value of $153,682.92. Following the completion of the sale, the director now owns 5,037 shares of the company's stock, valued at approximately $796,400.07. The trade was a 16.18 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,737 shares of company stock worth $2,879,752. 6.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have commented on the company. StockNews.com upgraded ICU Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, November 20th. Jefferies Financial Group upgraded ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 price objective for the company in a report on Wednesday, December 11th. KeyCorp upped their target price on shares of ICU Medical from $198.00 to $209.00 and gave the company an "overweight" rating in a research note on Wednesday, November 13th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $199.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.